What are bispecific antibodies?

In this week's video, Dr. Brian G.M. Durie explains how bispecific antibodies work and why they are being studied in clinical trials  to treat myeloma.

BOTTOM LINE:​
Bispecific antibodies are showing great promise in clinical trials.

If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected]

To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected]

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

 

Video
IMF TV Blog Category
Old Id
1536

Source URL: https://www.myeloma.org/videos/are-bispecific-antibodies